Vascular AMPK as an attractive target in the treatment of vascular complications of obesity

Vascular Pharmacology

Volumn 67, Issue , 2015, Pages 10-20

  Garcia Prieto C F ^a   Gil Ortega, M ^a   Aranguez I ^b   Ortiz Besoain, M ^c   Somoza, B ^a   Fernandez Alfonso M S ^b  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c UNIVERSIDAD CATÓLICA DEL NORTE   (Chile)

Author keywords

High fat diet; Obesity; Vascular AMPK

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETYLSALICYLIC ACID; ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; BERBERINE; EXENDIN 4; FATTY ACID; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PROTEIN KINASE; RESVERATROL; ROSIGLITAZONE; SIMVASTATIN; SITAGLIPTIN; UNCLASSIFIED DRUG; CARDIOVASCULAR AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

BLOOD VESSEL WALL; CALORIC RESTRICTION; CLINICAL TRIAL (TOPIC); DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXERCISE; GENETIC MODEL; HUMAN; LIFESTYLE MODIFICATION; LIPID DIET; MOLECULAR INTERACTION; MULTICENTER STUDY (TOPIC); NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE CELL; ADVERSE EFFECTS; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG DELIVERY SYSTEM; METABOLISM; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIET, HIGH-FAT; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; OBESITY; TREATMENT OUTCOME;

EID: 84929266270     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.02.017     Document Type: Review

References (149)

1. Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006, 119(10):812-819. 10.1016/j.amjmed.2006.02.031.
2. Hardie D.G., Scott J.W., Pan D.A., Hudson E.R. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 2003, 546(1):113-120. 10.1016/S0014-5793(03)00560-X.
3. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Müller C., Carling D., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415(6869):339-343. 10.1038/415339a.
4. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8(11):1288-1295. 10.1038/nm788.
5. Price N.L., Gomes A.P., Ling A.J., Duarte F.V., Martin-Montalvo A., North B.J., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012, 15(5):675-690. 10.1016/j.cmet.2012.04.003.
6. Xie Z., Dong Y., Zhang M., Cui M.Z., Cohen R.A., Riek U., et al. Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells. J Biol Chem 2006, 281(10):6366-6375. 10.1074/jbc.M511178200.
7. Zhang M., Dong Y., Xu J., Xie Z., Wu Y., Song P., et al. Thromboxane receptor activates the AMP-activated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ Res 2008, 102(3):328-337. 10.1161/CIRCRESAHA.107.163253.
8. Ewart M.A., Kennedy S. AMPK and vasculoprotection. Pharmacol Ther 2011, 131(2):242-253. 10.1016/j.pharmthera.2010.11.002.
9. Burkewitz K., Zhang Y., Mair W.B. AMPK at the nexus of energetics and aging. Cell Metab 2014, 20(1):10-25. 10.1016/j.cmet.2014.03.002.
10. Viollet B., Mounier R., Leclerc J., Yazigi A., Foretz M., Andreelli F. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 2007, 33(6):395-402. 10.1016/j.diabet.2007.10.004.
11. Lee W.J., Lee I.K., Kim H.S., Kim Y.M., Koh E.H., Won J.C., et al. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activate protein kinase. Arterioscler Thromb Vasc Biol 2005, 25:2488-2494. 10.1161/01.ATV.0000190667.33224.4c.
12. Ruderman N.B., Carling D., Prentki M., Cacicedo J.M. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 2013, 123(7):2764-2772. 10.1172/JCI67227.
13. Gauthier M.S., O'Brien E.L., Bigornia S., Mott M., Cacicedo J.M., Xu X.J., et al. Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans. Biochem Biophys Res Commun 2011, 404(1):382-387. 10.1016/j.bbrc.2010.11.127.
14. Hasenour C.M., Berglund E.D., Wasserman D.H. Emerging role of AMP-activated protein kinase in endocrine control of metabolism in the liver. Mol Cell Endocrinol 2013, 366(2):152-162. 10.1016/j.mce.2012.06.018.
15. Sanchez A.M., Candau R.B., Csibi A., Pagano A.F., Raibon A., Bernardi H. The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and energy homeostasis. Am J Physiol Cell Physiol 2012, 303(5):C475-C485. 10.1152/ajpcell. 00125.2012.
16. Fu A., Eberhard C.E., Screaton R.A. Role of AMPK in pancreatic beta cell function. Mol Cell Endocrinol 2013, 366(2):127-134. 10.1016/j.mce.2012.06.020.
17. Bijland S., Mancini S.J., Salt I.P. Role of AMP-activated protein kinase in adipose tissue metabolism and inflammation. Clin Sci (Lond) 2013, 124(8):491-507. 10.1042/CS20120536.
18. Zaha V.G., Young L.H. AMP-activated protein kinase regulation and biological actions in the heart. Circ Res 2012, 111(6):800-814. 10.1161/CIRCRESAHA.111.255505.
19. Dyck J.R., Gao G., Widmer J., Stapleton D., Fernandez C.S., Kemp B.E., et al. Regulation of 5'-AMP-activated protein kinase activity by the noncatalytic beta and gamma subunits. J Biol Chem 1996, 271(30):17798-17803. 10.1074/jbc.271.30.17798.
20. Fisslthaler B., Fleming I. Activation and signaling by the AMP-activated protein kinase in endothelial cells. Circ Res 2009, 105(2):114-127. 10.1161/CIRCRESAHA.109.201590.
21. Rubin L.J., Magliola L., Feng X., Jones A.W., Hale C.C. Metabolic activation of AMP kinase in vascular smooth muscle. J Appl Physiol 2005, 98(1):296-306. (1985). 10.1152/japplphysiol.00075.2004.
22. Goirand F., Solar M., Athea Y., Viollet B., Mateo P., Fortin D., et al. Activation of AMP kinase alpha1 subunit induces aortic vasorelaxation in mice. J Physiol 2007, 581(Pt 3):1163-1171. 10.1113/jphysiol.2007.132589.
23. Woods A., Johnstone S.R., Dickerson K., Leiper F.C., Fryer L.G., Neumann D., et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 2003, 13:2004-2008. 10.1016/j.cub.2003.10.031.
24. Long Y.C., Zierath J.R. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006, 116(7):1776-1783. 10.1172/JCI29044.
25. 2+/calmodulin-dependent protein kinase kinase beta. Mol Cell Biol 2006, 26(16):5933-5945. 10.1128/MCB.00383-06.
26. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100(3):328-341. 10.1161/01.RES.0000256090.42690.05.
27. Hawley S.A., Pan D.A., Mustard K.J., Ross L., Bain J., Edelman A.M., et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated proteinkinase. Cell Metab 2005, 2(1):9-19. 10.1016/j.cmet.2005.05.009.
28. Momcilovic M., Hong S.P., Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem 2006, 281(35):25336-25343. 10.1074/jbc.M604399200.
29. Cantó C., Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)?. Pharmacol Rev 2012, 64(1):166-187. 10.1124/pr.110.003905.
30. Chen Z., Peng I.C., Cui X., Li Y.S., Chien S., Shyy J.Y. Shear stress, SIRT1, and vascular homeostasis. Proc Natl Acad Sci U S A 2010, 107(22):10268-10273. 10.1073/pnas.1003833107.
31. Zhang J., Xie Z., Dong Y., Wang S., Liu C., Zou M.H. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J Biol Chem 2008, 283(41):27452-27461. 10.1074/jbc.M802578200.
32. Zou M.H., Wu Y. AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol 2008, 35(5-6):535-545. 10.1111/j.1440-1681.2007.04851.x.
33. Michell B.J., Zp Chen, Tiganis T., Stapleton D., Katsis F., Power D.A., et al. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 2001, 276(21):17625-17628. 10.1074/jbc.C100122200.
34. Wu Y., Song P., Xu J., Zhang M., Zou M.H. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. J Biol Chem 2007, 282(13):9777-9788. 10.1074/jbc.M608310200.
35. Ylikorkala A., Rossi D.J., Korsisaari N., Luukko K., Alitalo K., Henkemeyer M., et al. Vascular abnormalities and dysregulation of VEGF in Lkb1-deficient mice. Science 2001, 293(5533):1323-1326. 10.1126/science.1062074.
36. Lee K.Y., Choi H.C. Acetylcholine-induced AMP-activated protein kinase activation attenuates vasoconstriction through an LKB1-dependent mechanism in rat aorta. Vascul Pharmacol 2013, 59(3-4):96-102. 10.1016/j.vph.2013.07.007.
37. Chang M.Y., Ho F.M., Wang J.S., Kang H.C., Chang Y., Ye Z.X., et al. AICAR induces cyclooxygenase-2 expression through AMP-activated protein kinase-transforming growth factor-beta-activated kinase 1-p38 mitogen-activated protein kinase signaling pathway. Biochem Pharmacol 2010, 80(8):1210-1220. 10.1016/j.bcp.2010.06.049.
38. Kim E.J., Choi Y.K., Han Y.H., Kim H.J., Lee I.K., Lee M.O. RORα suppresses proliferation of vascular smooth muscle cells through activation of AMP-activated proteinkinase. Int J Cardiol 2014, 175(3):515-521. 10.1016/j.ijcard.2014.06.043.
39. Miyabe M., Ohashi K., Shibata R., Uemura Y., Ogura Y., Yuasa D., et al. Muscle-derived follistatin-like 1 functions to reduce neointimal formation after vascular injury. Cardiovasc Res 2014, 103(1):111-120. 10.1093/cvr/cvu105.
40. Davis B.J., Xie Z., Viollet B., Zou M.H. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 2006, 55(2):496-505. 10.2337/diabetes.55.02.06.db05-1064.
41. Morrow V.A., Foufelle F., Connell J.M., Petrie J.R., Gould G.W., Salt I.P. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 2003, 278:31629-31639. 10.1074/jbc.M212831200.
42. Chen Z., Peng I.C., Sun W., Su M.I., Hsu P.H., Fu Y., et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 2009, 104:496-505. 10.1161/CIRCRESAHA.108.187567.
43. Wang Y., Huang Y., Lam K.S., Li Y., Wong W.T., Ye H., et al. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. Cardiovasc Res 2009, 82(3):484-492. 10.1093/cvr/cvp078.
44. Bradley E.A., Eringa E.C., Stehouwer C.D.A., Korstjens I., van Nieuw Amerongen G.P., Musters R., et al. Activation of AMP-activated protein kinase by 5-minoimidazole-4-carboxamide-1-beta-d-ribofuranoside in the muscle microcirculation increases nitric oxide synthesis and microvascular perfusion. Arterioscler Thromb Vasc Biol 2010, 30:1137-1142. 10.1161/ATVBAHA.110.204404.
45. Bosselaar M., Boon H., van Loon L.J., van den Broek P.H., Smits P., Tack C.J. Intra-arterial AICA-riboside administration induces NO-dependent vasodilation in vivo in human skeletal muscle. Endocrinol Metab 2009, 297:E759-E766. 10.1152/ajpendo.00141.2009.
46. Levine Y.C., Li G.K., Michel T. Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells: evidence for an AMPK/Rac1/Akt/endothelial nitric-oxide synthase pathway. J Biol Chem 2007, 282(28):20351-20364. 10.1074/jbc.M702182200.
47. Ning W.H., Zhao K. Propionyl-l-carnitine induces eNOS activation and nitric oxide synthesis in endothelial cells via PI3 and Akt kinases. Vascul Pharmacol 2013, 59(3-4):76-82. 10.1016/j.vph.2013.07.001.
48. García-Prieto C.F., Hernández-Nuño F., Rio D.D., Ruiz-Hurtado G., Aránguez I., Ruiz-Gayo M., et al. High-fat diet induces endothelial dysfunction through a down-regulation of the endothelial AMPK-PI3K-Akt-eNOS pathway. Mol Nutr Food Res 2015, 59(3):520-532. 10.1002/mnfr.201400539.
49. Deng G., Long Y., Yu Y.R., Li M.R. Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes (Lond) 2010, 34(1):165-171. 10.1038/ijo.2009.205.
50. Schulz E., Anter E., Zou M.H., Keaney J.F. Estradiol-mediated endothelial nitric oxide synthase association with heat shock protein 90 requires adenosine monophosphate-dependent protein kinase. Circulation 2005, 111(25):3473-3480. 10.1161/CIRCULATIONAHA.105.546812.
51. Procopio C., Andreozzi F., Laratta E., Cassese A., Beguinot F., Arturi F., et al. Leptin-stimulated endothelial nitric-oxide synthase via an adenosine 5'-monophosphate-activated proteinkinase/Akt signaling pathway is attenuated by interaction with C-reactive protein. Endocrinology 2009, 150(8):3584-3593. 10.1210/en.2008-0921.
52. Rojas E., Rodríguez-Molina D., Bolli P., Israili Z.H., Faría J., Fidilio E., et al. The role of adiponectin in endothelial dysfunction and hypertension. Curr Hypertens Rep 2014, 16(8):463. 10.1007/s11906-014-0463-7.
53. Xie Z., Dong Y., Scholz R., Neumann D., Zou M.H. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation 2008, 117(7):952-962. 10.1161/CIRCULATIONAHA.107.744490.
54. Boyle J.G., Logan P.J., Ewart M.A., Reihill J.A., Ritchie S.A., Connell J.M., et al. Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J Biol Chem 2008, 283(17):11210-11217. 10.1074/jbc.M710048200.
55. Takeuchi K., Morizane Y., Kamami-Levy C., Suzuki J., Kayama M., Cai W., et al. AMP-dependent kinase inhibits oxidative stress-induced caveolin-1 phosphorylation and endocytosis by suppressing the dissociation between c-Abl and Prdx1 proteins in endothelial cells. J Biol Chem 2013, 288(28):20581-20591. 10.1074/jbc.M113.460832.
56. Kröller-Schön S., Jansen T., Hauptmann F., Schüler A., Heeren T., Hausding M., et al. α1AMP-activated protein kinase mediates vascular protective effects of exercise. Arterioscler Thromb Vasc Biol 2012, 32(7):1632-1641. 10.1161/ATVBAHA.111.243980.
57. Li X.N., Song J., Zhang L., LeMaire S.A., Hou X., Zhang C., et al. Activation of the AMPK-FOXO3 pathway reduces fatty acid-induced increase in intracellular reactive oxygen species by upregulating thioredoxin. Diabetes 2009, 58(10):2246-2257. 10.2337/db08-1512.
58. Ido Y., Carling D., Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 2002, 51(1):159-167. 10.2337/diabetes.51.1.159.
59. Ouslimani N., Peynet J., Bonnefont-Rousselot D., Thérond P., Legrand A., Beaudeux J.L. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 2005, 54(6):829-834. 10.1016/j.metabol.2005.01.029.
60. Colombo S.L., Moncada S. AMPKalpha1 regulates the antioxidant status of vascular endothelial cells. Biochem J 2009, 421(2):163-169. 10.1042/BJ20090613.
61. Kukidome D., Nishikawa T., Sonoda K., Imoto K., Fujisawa K., Yano M., et al. Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial reactive oxygen species production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells. Diabetes 2006, 55(1):120-127. 10.2337/diabetes.55.01.06.db05-0943.
62. Dagher Z., Ruderman N., Tornheim K., Ido Y. Acute regulation of fatty acid oxidation and amp-activated protein kinase in human umbilical vein endothelial cells. Circ Res 2001, 88(12):1276-1282. 10.1161/hh1201.092998.
63. McCarty M.F. AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome. Med Hypotheses 2005, 64(6):1211-1215. 10.1016/j.mehy.2004.01.042.
64. Inoguchi T., Li P., Umeda F., Yu H.Y., Kakimoto M., Imamura M., et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49(11):1939-1945. 10.2337/diabetes.49.11.1939.
65. Nagata D., Mogi M., Walsh K. AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. J Biol Chem 2003, 278(33):31000-31006. 10.1074/jbc.M300643200.
66. Majithiya J.B., Balaraman R. Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats. Life Sci 2006, 78(22):2615-2624. 10.1016/j.lfs.2005.10.020.
67. Motoshima H., Goldstein B.J., Igata M., Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006, 574(Pt 1):63-71. 10.1113/jphysiol.2006.108324.
68. Igata M., Motoshima H., Tsuruzoe K., Kojima K., Matsumura T., Kondo T., et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005, 97(8):837-844. 10.1161/01.RES.0000185823.73556.06.
69. Snell-Bergeon J.K., Budoff M.J., Hokanson J.E. Vascular calcification in diabetes: mechanisms and implications. Curr Diab Rep 2013, 13(3):391-402. 10.1007/s11892-013-0379-7.
70. Zhan J.K., Wang Y.J., Wang Y., Tang Z.Y., Tan P., Huang W., et al. Adiponectin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the AMPK/mTOR pathway. Exp Cell Res 2014, 323(2):352-358. 10.1016/j.yexcr.2014.02.016.
71. Cao X., Li H., Tao H., Wu N., Yu L., Zhang D., et al. Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the AMPK-eNOS-NO pathway. Endocrinology 2013, 154(10):3680-3689. 10.1210/en.2013-1002.
72. Kim S.A., Choi H.C. Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells. Biochem Biophys Res Commun 2012, 425(4):866-872. 10.1016/j.bbrc.2012.07.165.
73. Stapleton P.A., James M.E., Goodwill A.G., Frisbee J.C. Obesity and vascular dysfunction. Pathophysiology 2008, 15(2):79-89. 10.1016/j.pathophys.2008.04.007.
74. Klop B., Elte J.W., Cabezas M.C. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients 2013, 5(4):1218-1240. 10.3390/nu5041218.
75. Li H., Li H., Bao Y., Zhang X., Yu Y. Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-κB pathway in rat aorta. Int J Cardiol 2011, 152(2):218-224. 10.1016/j.ijcard.2010.07.019.
76. Artwohl M., Roden M., Waldhäusl W., Freudenthaler A., Baumgartner-Parzer S.M. Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. FASEB J 2004, 18(1):146-148. 10.1096/fj.03-0301fje.
77. Ruderman N.B., Cacicedo J.M., Itani S., Yagihashi N., Saha A.K., Ye J.M., et al. Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem Soc Trans 2003, 31(Pt 1):202-206. [PMID: 12546685].
78. Lamers D., Schlich R., Horrighs A., Cramer A., Sell H., Eckel J. Differential impact of oleate, palmitate, and adipokines on expression of NF-κB target genes in human vascular smooth muscle cells. Mol Cell Endocrinol 2012, 362(1-2):194-201. 10.1016/j.mce.2012.06.010.
79. Cacicedo J.M., Yagihashi N., Keaney J.F., Ruderman N.B., Ido Y. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem Biophys Res Commun 2004, 324(4):1204-1209. 10.1016/j.bbrc.2004.09.177.
80. Staiger H., Staiger K., Stefan N., Wahl H.G., Machicao F., Kellerer M., et al. Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. Diabetes 2004, 53(12):3209-3216. 10.2337/diabetes.53.12.3209.
81. Weikel K.A., Cacicedo J., Ruderman N.B., Ido Y. Glucose and palmitate uncouple AMPK from autophagy in human aortic endothelial cells. Am J Physiol Cell Physiol 2014, 10.1152/ajpcell.00265.2014.
82. Meijer R.I., Bakker W., Alta C.L., Sipkema P., Yudkin J.S., Viollet B., et al. Perivascular adipose tissue control of insulin-induced vasoreactivity in muscle is impaired in db/db mice. Diabetes 2013, 62(2):590-598. 10.2337/db11-1603.
83. Ma L., Ma S., He H., Yang D., Chen X., Luo Z., et al. Perivascular fat-mediated vascular dysfunction and remodeling through the AMPK/mTOR pathway in high-fat diet-induced obese rats. Hypertens Res 2010, 33(5):446-453. 10.1038/hr.2010.11.
84. Lobato N.S., Filgueira F.P., Prakash R., Giachini F.R., Ergul A., Carvalho M.H., et al. Reduced endothelium-dependent relaxation to anandamide in mesenteric arteries from young obese Zucker rats. PLoS One 2013, 8(5):e63449. 10.1371/journal.pone.0063449.
85. Ko H.J., Zhang Z., Jung D.Y., Jun J.Y., Ma Z., Jones K.E., et al. Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes 2009, 58(11):2536-2546. 10.2337/db08-1361.
86. Blume C., Benz P.M., Walter U., Ha J., Kemp B.E., Renné T. AMP-activated protein kinase impairs endothelial actin cytoskeleton assembly by phosphorylating vasodilator-stimulated phosphoprotein. J Biol Chem 2007, 282(7):4601-4612. 10.1074/jbc.M608866200.
87. Culic O., Decking U.K., Schrader J. Metabolic adaptation of endothelial cells to substrate deprivation. Am J Physiol 1999, 276(5 Pt 1):C1061-C1068. [PMID: 10329953].
88. Sarabi M., Fugmann A., Karlström B., Berne C., Lithell H., Lind L. An ordinary mixed meal transiently impairs endothelium-dependent vasodilation in healthy subjects. Acta Physiol Scand 2001, 172(2):107-113. 10.1046/j.1365-201X.2001.00845.x.
89. McCarty M.F. Does postprandial storage of triglycerides in endothelial cells contribute to the endothelial dysfunction associated with insulin resistance and fatty diets?. Med Hypotheses 2003, 61(2):167-172. 10.1016/S0306-9877(02)00236-0.
90. Yu H.Y., Inoguchi T., Kakimoto M., Nakashima N., Imamura M., Hashimoto T., et al. Saturated non-esterified fatty acids stimulate de novo diacylglycerol synthesis and protein kinase c activity in cultured aortic smooth muscle cells. Diabetologia 2001, 44(5):614-620. 10.1007/s001250051668.
91. Sugiyama S., Kugiyama K., Ogata N., Doi H., Ota Y., Ohgushi M., et al. Biphasic regulation of transcription factor nuclear factor-kappaB activity in human endothelial cells by lysophosphatidylcholine through protein kinase C-mediated pathway. Arterioscler Thromb Vasc Biol 1998, 18(4):568-576. 10.1161/01.ATV.18.4.568.
92. Lu Y., Qian L., Zhang Q., Chen B., Gui L., Huang D., et al. Palmitate induces apoptosis in mouse aortic endothelial cells and endothelial dysfunction in mice fed high-calorie and high-cholesterol diets. Life Sci 2013, 92(24-26):1165-1173. 10.1016/j.lfs.2013.05.002.
93. Viollet B., Andreelli F. AMP-activated protein kinase and metabolic control. Handb Exp Pharmacol 2011, 203:303-330. 10.1007/978-3-642-17214-4_13.
94. Cacicedo J.M., Gauthier M.S., Lebrasseur N.K., Jasuja R., Ruderman N.B., Ido Y. Acute exercise activates AMPK and eNOS in the mouse aorta. Am J Physiol Heart Circ Physiol 2011, 301(4):H1255-H1265. 10.1152/ajpheart.01279.2010.
95. Gu Q., Wang B., Zhang X.F., Ma Y.P., Liu J.D., Wang X.Z. Chronic aerobic exercise training attenuates aortic stiffening and endothelial dysfunction through preserving aortic mitochondrial function in aged rats. Exp Gerontol 2014, 56:37-44. 10.1016/j.exger.2014.02.014.
96. Pires R.C., Souza E.E., Vanzela E.C., Ribeiro R.A., Silva-Santos J.C., Carneiro E.M., et al. Short-term calorie restriction improves glucose homeostasis in old rats: involvement of AMPK. Appl Physiol Nutr Metab 2014, 39(8):895-901. 10.1139/apnm-2013-0520.
97. Kondo M., Shibata R., Miura R., Shimano M., Kondo K., Li P., et al. Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. J Biol Chem 2009, 284(3):1718-1724. 10.1074/jbc.M805301200.
98. Dolinsky V.W., Morton J.S., Oka T., Robillard-Frayne I., Bagdan M., Lopaschuk G.D., et al. Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension 2010, 56(3):412-421. 10.1161/HYPERTENSIONAHA.110.154732.
99. García-Prieto C.F., Pulido-Olmo H., Ruiz-Hurtado G., Gil-Ortega M., Aranguez I., Rubio M.A., et al. Mild caloric restriction reduces blood pressure and activates endothelial AMPK-PI3K-Akt-eNOS pathway in obese Zucker rats. Vascul Pharmacol 2015, 65-66:3-12. 10.1016/j.vph.2014.12.001.
100. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346(6):393-403. 10.1056/NEJMoa012512.
101. Baker M.K., Simpson K., Lloyd B., Bauman A.E., Singh M.A. Behavioral strategies in diabetes prevention programs: a systematic review of randomized controlled trials. Diabetes Res Clin Pract 2011, 91(1):1-12. 10.1016/j.diabres.2010.06.030.
102. Redmon J.B., Bertoni A.G., Connelly S., Feeney P.A., Glasser S.P., Glick H., et al. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular diseaserisk factors in individuals with type 2 diabetes. Diabetes Care 2010, 33(6):1153-1158. 10.2337/dc09-2090.
103. Kitada M., Kume S., Takeda-Watanabe A., Tsuda S., Kanasaki K., Koya D. Calorie restriction in overweight males ameliorates obesity-related metabolic alterations and cellular adaptations through anti-aging effects, possibly including AMPK and SIRT1 activation. Biochim Biophys Acta 2013, 1830(10):4820-4827. 10.1016/j.bbagen.2013.06.014.
104. Golbidi S., Badran M., Laher I. Diabetes and alpha lipoic Acid. Front Pharmacol 2011, 2:69. 10.3389/fphar.2011.00069.
105. Park K.G., Min A.K., Koh E.H., Kim H.S., Kim M.O., Park H.S., et al. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology 2008, 48(5):1477-1486. 10.1002/hep.22496.
106. Kim M.S., Park J.Y., Namkoong C., Jang P.G., Ryu J.W., Song H.S., et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 2004, 10(7):727-733. 10.1038/nm1061.
107. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55(6):1577-1596. 10.1007/s00125-012-2534-0.
108. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108(8):1167-1174. 10.1172/JCI13505.
109. Matsumoto T., Noguchi E., Ishida K., Kobayashi T., Yamada N., Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 2008, 295(3):H1165-H1176. 10.1152/ajpheart.00486.2008.
110. Enkhjargal B., Godo S., Sawada A., Suvd N., Saito H., Noda K., et al. Endothelial AMP-activated protein kinase regulates blood pressure and coronary flow responses through hyperpolarization mechanism in mice. Arterioscler Thromb Vasc Biol 2014, 34(7):1505-1513. 10.1161/ATVBAHA.114.303735.
111. Cheang W.S., Tian X.Y., Wong W.T., Lau C.W., Lee S.S., Chen Z.Y., et al. Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5' adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor δ pathway. Arterioscler Thromb Vasc Biol 2014, 34(4):830-836. 10.1161/ATVBAHA.113.301938.
112. Tian X.Y., Wong W.T., Wang N., Lu Y., Cheang W.S., Liu J., et al. PPARδ activation protects endothelial function in diabetic mice. Diabetes 2012, 61(12):3285-3293. 10.2337/db12-0117.
113. Ceolotto G., Gallo A., Papparella I., Franco L., Murphy E., Iori E., et al. Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism. Arterioscler Thromb Vasc Biol 2007, 27(12):2627-2633. 10.1161/ATVBAHA.107.155762.
114. Morisaki K., Shibata R., Takahashi N., Ouchi N., Maehara Y., Murohara T., et al. Pioglitazone prevents intimal hyperplasia in experimental rabbit vein grafts. J Vasc Surg 2011, 54(6):1753-1759. 10.1016/j.jvs.2011.06.081.
115. Dong Y., Zhang M., Wang S., Liang B., Zhao Z., Liu C., et al. Activation of AMP-activated protein kinase inhibits oxidized LDL-triggered endoplasmic reticulum stress in vivo. Diabetes 2010, 59(6):1386-1396. 10.2337/db09-1637.
116. Ozcan U., Cao Q., Yilmaz E., Lee A.H., Iwakoshi N.N., Ozdelen E., et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004, 306(5695):457-461. 10.1126/science.1103160.
117. Svegliati-Baroni G., Saccomanno S., Rychlicki C., Agostinelli L., De Minicis S., Candelaresi C., et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int 2011, 31(9):1285-1297. 10.1111/j.1478-3231.2011.02462.x.
118. Lee J., Hong S.W., Chae S.W., Kim D.H., Choi J.H., Bae J.C., et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One 2012, 7(2):e31394. 10.1371/journal.pone.0031394.
119. Astrup A., Rössner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374(9701):1606-1616. 10.1016/S0140-6736(09)61375-1.
120. Burmeister M.A., Ayala J., Drucker D.J., Ayala J.E. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose. Am J Physiol Endocrinol Metab 2013, 304(7):E677-E685. 10.1152/ajpendo.00446.2012.
121. Vilsbøll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344:d7771. 10.1136/bmj.d7771.
122. Zeng Y., Li C., Guan M., Zheng Z., Li J., Xu W., et al. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. Cardiovasc Diabetol 2014, 13:32. 10.1186/1475-2840-13-32.
123. Krasner N.M., Ido Y., Ruderman N.B., Cacicedo J.M. Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One 2014, 9(5):e97554. 10.1371/journal.pone.0097554.
124. Han L., Yu Y., Sun X., Wang B. Exendin-4 directly improves endothelial dysfunction in isolated aortas from obese rats through the cAMP or AMPK-eNOS pathways. Diabetes Res Clin Pract 2012, 97(3):453-460. 10.1016/j.diabres.2012.04.001.
125. Rossoni L.V., Wareing M., Wenceslau C.F., Al-Abri M., Cobb C., Austin C. Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. Clin Sci (Lond) 2011, 121(10):449-458. 10.1042/CS20110259.
126. Sun W., Lee T.S., Zhu M., Gu C., Wang Y., Zhu Y., et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006, 114(24):2655-2662. 10.1161/CIRCULATIONAHA.106.630194.
127. Li X., Han Y., Pang W., Li C., Xie X., Shyy J.Y., et al. AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008, 28(10):1789-1795. 10.1161/ATVBAHA.108.172452.
128. Corton J.M., Gillespie J.G., Hawley S.A., Hardie D.G. 5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating AMP-activated protein kinase in intact cells?. Eur J Biochem 1995, 229:558-565. 10.1111/j.1432-1033.1995.0558k.x.
129. Song X.M., Fiedler M., Galuska D., Ryder J.W., Fernström M., Chibalin A.V., et al. 5-Aminoimidazole-4-carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia 2002, 45(1):56-65. 10.1007/s001250200006.
130. Bergeron R., Previs S.F., Cline G.W., Perret P., Russell R.R., Young L.H., et al. Effect of 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001, 50(5):1076-1082. 10.2337/diabetes.50.5.1076.
131. Iglesias M.A., Ye J.M., Frangioudakis G., Saha A.K., Tomas E., Ruderman N.B., et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002, 51(10):2886-2894. 10.2337/diabetes.51.10.2886.
132. Ford R.J., Teschke S.R., Reid E.B., Durham K.K., Kroetsch J.T., Rush J.W. AMP-activated protein kinase activator AICAR acutely lowers blood pressure and relaxes isolated resistance arteries of hypertensive rats. J Hypertens 2012, 30(4):725-733. 10.1097/HJH.0b013e32835050ca.
133. Bosselaar M., Smits P., van Loon L.J., Tack C.J. Intravenous AICAR during hyperinsulinemia induces systemic hemodynamic changes but has no local metabolic effect. J Clin Pharmacol 2011, 51(10):1449-1458. 10.1177/0091270010382912.
134. Igata M., Motoshima H., Tsuruzoe K., Kojima K., Matsumura T., Kondo T., et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 2005, 97(8):837-844. 10.1161/01.RES.0000185823.73556.06.
135. Nagata D., Takeda R., Sata M., Satonaka H., Suzuki E., Nagano T., et al. AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 2004, 110(4):444-451. 10.1161/01.CIR.0000136025.96811.76.
136. Kim J.E., Song S.E., Kim Y.W., Kim J.Y., Park S.C., Park Y.K., et al. Adiponectin inhibits palmitate-induced apoptosis through suppression of reactive oxygen species in endothelial cells: involvement of cAMP/protein kinase A and AMP-activated protein kinase. J Endocrinol 2010, 207(1):35-44. 10.1677/JOE-10-0093.
137. Gaskin F.S., Kamada K., Yusof M., Korthuis R.J. 5'-AMP-activated protein kinase activation prevents postischemic leukocyte-endothelial cell adhesive interactions. Am J Physiol Heart Circ Physiol 2007, 292(1):H326-H332. 10.1152/ajpheart.00744.2006.
138. Ewart M.A., Kohlhaas C.F., Salt I.P. Inhibition of tumor necrosis factor alpha-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase. Arterioscler Thromb Vasc Biol 2008, 28(12):2255-2257. 10.1161/ATVBAHA. 108.175919.
139. Li D., Wang D., Wang Y., Ling W., Feng X., Xia M. Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem 2010, 285(43):33499-33509. 10.1074/jbc.M110.159772.
140. Goff D., Payan D., Singh R., Shaw S., Carroll D., Hitoshi Y. AMPK-activating heterocyclic compounds and methods for using the same 2012, Rigel Pharmaceuticals, San Francisco, CA. Organization WIP (Ed.).
141. Baltgalvis K.A., White K., Li W., Claypool M.D., Lang W., Alcantara R., et al. Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice. Am J Physiol Heart Circ Physiol 2014, 306(8):H1128-H1145. 10.1152/ajpheart.00839.2013.
142. Sung J.Y., Choi H.C. Aspirin-induced AMP-activated protein kinase activation regulates the proliferation of vascular smooth musclecells from spontaneously hypertensive rats. Biochem Biophys Res Commun 2011, 408(2):312-317. 10.1016/j.bbrc.2011.04.027.
143. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444(7117):337-342. 10.1038/nature05354.
144. Rivera L., Morón R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharmacol 2009, 77(6):1053-1063. 10.1016/j.bcp.2008.11.027.
145. Kanamori H., Takemura G., Goto K., Tsujimoto A., Ogino A., Takeyama T., et al. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am J Pathol 2013, 182(3):701-713. 10.1016/j.ajpath.2012.11.009.
146. Jeong H.W., Hsu K.C., Lee J.W., Ham M., Huh J.Y., Shin H.J., et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 2009, 296(4):E955-E964. 10.1152/ajpendo.90599.2008.
147. Sasaki H., Asanuma H., Fujita M., Takahama H., Wakeno M., Ito S., et al. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009, 119(19):2568-2577. 10.1161/CIRCULATIONAHA.108.798561.
148. Li Y., Chen C., Yao F., Su Q., Liu D., Xue R., et al. AMPK inhibits cardiac hypertrophy by promoting autophagy via mTORC1. Arch Biochem Biophys 2014, 558:79-86. 10.1016/j.abb.2014.06.023.
149. Franciosi M., Lucisano G., Lapice E., Strippoli G.F., Pellegrini F., Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013, 8(8):e71583. 10.1371/journal.pone.0071583.